Clinical Trial: Lemborexant for Cannabis Use Disorder

U.S., Sept. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07802990) titled 'Lemborexant for Cannabis Use Disorder' on Aug. 24.

Brief Summary: The goal of this clinical trial is to investigate the use of Lemborexant as a treatment for moderate to severe Cannabis Use Disorder (CUD). The main questions it aims to answer are:

1. Is Lemborexant safe, feasible, and tolerable to use in the CUD population?

2. Will the use of Lemborexant for CUD help to decrease cannabis use, improve sleep, decrease cannabis withdrawal symptoms, and improve cognition?

Researchers will compare 10mg Lemborexant to placebo.

Participants will:

* Take 10mg Lemborexant (or placebo) nightly for 21 nights (treatment phase).

* Wear an ...